Interstitial Lung Diseases Clinical Trials

8 recruiting

Interstitial Lung Diseases Trials at a Glance

14 actively recruiting trials for interstitial lung diseases are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Milan, Essen, and Boston. Lead sponsors running interstitial lung diseases studies include Boehringer Ingelheim, Gazi University, and First Affiliated Hospital of Wenzhou Medical University.

Browse interstitial lung diseases trials by phase

Treatments under study

About Interstitial Lung Diseases Clinical Trials

Looking for clinical trials for Interstitial Lung Diseases? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Interstitial Lung Diseases trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Interstitial Lung Diseases clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 3

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Interstitial Lung DiseasesSystemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim400 enrolled158 locationsNCT06806592
Recruiting
Phase 3

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Interstitial Lung DiseasesFamilial Pulmonary FibrosisInterstitial Lung Abnormalities
Boehringer Ingelheim80 enrolled56 locationsNCT07201922
Recruiting
Phase 2Phase 3

Anlotinib Capsules in the Treatment for IPF/PF-ILDs

Interstitial Lung Diseases
First Affiliated Hospital of Wenzhou Medical University30 enrolled1 locationNCT05828953
Recruiting

Interstitial Lung Disease: A Study From Infancy to Elderly Including Relatives

Interstitial Lung Diseases
Institut National de la Santé Et de la Recherche Médicale, France3,000 enrolled1 locationNCT06036719
Recruiting

Advanced Mutidimensional and Ultra High Resolution Computed Tomography to Inspect Cardiopulmonary Involvement in Progressive Fibrosing Interstitial Lung Diseases

Interstitial Lung Diseases
IRCCS San Raffaele123 enrolled1 locationNCT06537934
Recruiting
Not Applicable

Safety and Performance Profile of Cryobiopsy in Bronchial Endoscopy

Mediastinal LymphadenopathyMediastinal LesionsDiffuse Interstitial Lung Diseases
University Hospital, Strasbourg, France30 enrolled1 locationNCT07301697
Recruiting
Not Applicable

Functional MRI for Monitoring Progression and Assessing Trends in ILD

Interstitial Lung Diseases (ILD)
University Hospital Heidelberg200 enrolled2 locationsNCT07300696
Recruiting
Not Applicable

Treatable Traits in Interstitial Lung Disease

Interstitial Lung Diseases (ILD)
The University of Western Australia110 enrolled2 locationsNCT06626438
Recruiting
Not Applicable

Ultrasound and Respiratory Physiological Signals in Lung Diseases

UltrasoundChronic Obstructive Pulmonary DiseaseInterstitial Lung Disease+5 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS25 enrolled1 locationNCT06068647
Recruiting

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

SarcoidosisIdiopathic Pulmonary FibrosisInterstitial Lung Diseases+1 more
University of Chicago4,000 enrolled1 locationNCT00470327
Recruiting

Exercise Capacity, Muscle Oxygenation, and Physical Activity Between Patients With Interstitial Lung Disease

Healthy IndividualsInterstitial Lung Diseases (ILD)
Gazi University40 enrolled1 locationNCT06948942
Recruiting

Validity and Reliability of 6-minute Pegboard and Ring Test in Patients With Interstitial Lung Disease

Interstitial Lung Diseases (ILD)
Gazi University34 enrolled1 locationNCT06948916
Recruiting

MucinB5 Gene Polymorphism and Leucocytes Telomere Length in Interstitial Lung Diseases

Mucin B5 rs (35705950) Gene Polymorphism in Interstitial Lung Diseases
Sohag University100 enrolled1 locationNCT06498141
Recruiting

LetS Get fUnctional! FuNctional Status in pEople With intersTitial Lung Disease

Interstitial Lung Diseases
Aveiro University150 enrolled1 locationNCT06317831